PT  - JOURNAL ARTICLE
AU  - Cong Zeng
AU  - John P. Evans
AU  - Sarah Reisinger
AU  - Jennifer Woyach
AU  - Christina Liscynesky
AU  - Zeinab El Boghdadly
AU  - Mark P. Rubinstein
AU  - Karthik Chakravarthy
AU  - Linda Saif
AU  - Eugene M. Oltz
AU  - Richard J. Gumina
AU  - Peter G. Shields
AU  - Zihai Li
AU  - Shan-Lu Liu
TI  - Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccines in Cancer Patients
AID  - 10.1101/2021.10.20.21265273
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.20.21265273
4099  - http://medrxiv.org/content/early/2021/10/21/2021.10.20.21265273.short
4100  - http://medrxiv.org/content/early/2021/10/21/2021.10.20.21265273.full
AB  - There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), after they received two doses of mRNA vaccines. Serum from 46 mRNA vaccinated health care workers (HCWs) served as healthy controls. We discovered that (1) cancer patients exhibited reduced neutralizing antibody titer (NT50) compared to HCWs; (2) CLL and NHL patients exhibited the lowest NT50 levels, with 50-60% of them below the detection limit; (3) mean NT50 levels in patients with CLL and NHL was ∼2.6 fold lower than those with solid tumors; and (4) cancer patients who received anti-B cell therapy exhibited significantly reduced NT50 levels. Our results demonstrate an urgent need for novel immunization strategies for cancer patients against SARS-CoV-2, particularly those with hematological cancers and those on anti-B cell therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NCI U54CA260582, NIH R01 AI150473, NIH R01 HL127442-01A1Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of OSU gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors